Compare WT & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WT | ANIP |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2011 | 1999 |
| Metric | WT | ANIP |
|---|---|---|
| Price | $18.37 | $82.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.33 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 3.3M | 291.7K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | 127.27 | ★ 419.23 |
| EPS | 0.75 | ★ 3.32 |
| Revenue | ★ $493,753,000.00 | $206,547,000.00 |
| Revenue This Year | $35.04 | $21.01 |
| Revenue Next Year | $8.68 | $17.59 |
| P/E Ratio | ★ $23.27 | $24.37 |
| Revenue Growth | ★ 15.43 | 2.47 |
| 52 Week Low | $8.18 | $56.71 |
| 52 Week High | $17.87 | $99.50 |
| Indicator | WT | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 70.09 | 63.35 |
| Support Level | $13.07 | $77.77 |
| Resistance Level | N/A | $83.87 |
| Average True Range (ATR) | 0.74 | 2.77 |
| MACD | 0.37 | 0.52 |
| Stochastic Oscillator | 96.85 | 95.52 |
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.